Latest technology news and innovations
A notable drop in GLP-1 drug coverage among U.S. employers coincides with a decline in Massachusetts' biotech workforce, highlighting industry challenges.
Recent analyses indicate that post-Dobbs predictions about abortion rates and health impacts may not align with current realities.
Roche's significant investment in the U.S. coincides with heightened demand for estrogen patches, now facing severe production challenges.
Recent observations suggest cancer patients might be receiving unwarranted high doses and lengthy treatments of costly medications.
With Ebola cases rising sharply in the DRC, Merck's vaccine is set for deployment to enhance response efforts, including a significant clinical trial.
Focal therapy is increasingly considered in prostate cancer treatment, offering a targeted approach with fewer side effects than traditional methods.
Lil Nas X's bipolar diagnosis highlights a troubling paradox where acknowledgment of distress often clashes with the pursuit of success and treatment fears.
Long-term HIV survivors worry that a cure might jeopardize their essential support services, highlighting the need for thoughtful policy considerations.
Regeneron and Ultragenyx receive FDA approvals for significant therapies aimed at rare diseases, offering new hope for affected patients.
The recent success of Merck and Moderna's personalized mRNA cancer therapy marks a pivotal moment in cancer treatment advancements.
Healthcare providers are increasingly adopting AI chatbots to navigate complex patient records, improving diagnosis and patient care.
Erica Schwartz, the new CDC director, emphasizes transparency and empowerment in her inaugural address, ready to challenge administration leaders as needed.
STAT launches strategic roles and initiatives to combat misinformation and rebuild public trust in science, led by seasoned journalist Nicholas Florko.
Regeneron's new drug, Pasatru, is approved to treat fibrodysplasia ossificans progressiva, aiming to significantly improve patient outcomes.
The ACS has canceled its Wine and Spirits Industry Gala, reconsidering fundraising methods amid concerns over conflicts with its mission.
A Harvard team has kept brain organoids alive for over five years, revealing developmental insights that advance our understanding of human brains.
Epic's annual meeting revealed new customer partnerships and engaging presentations, but left attendees wanting more on AI developments.
Moderna and Merck announced positive findings from a late-stage melanoma trial using a personalized mRNA vaccine, potentially transforming cancer treatment.
Experts weigh in on the controversial gene editing trial by Huidagene, offering mixed reviews of the science behind it after a tragic incident.
The FTC is investigating Epic Systems for potential antitrust violations related to its market dominance and employment contracts.